Sun Pharma Announces Settlement of Litigation Over Generic Exelon

MUMBAI, India, Dec. 6, 2007-Sun Pharmaceutical Industries Ltd. announced that it has executed a settlement agreement with Novartis stipulating a dismissal of the lawsuits filed in the United States against the Company regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Exelon, rivastigmine tartrate capsules.

Earlier, USFDA had granted final approval for the Company's ANDA to market its generic Exelon®.

Under the terms of the settlement agreement, Sun Pharma will not market generic Exelon® in the U.S. until sometime prior to the expiration of the patents covering Exelon®. The specific date on which Sun may launch and the other terms of the agreement are confidential.

Exelon ® is a registered trademark of Novartis.

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Dear Recipient

You have received this email as your address is part of our Investor Relations and Media Contacts list. All our Press Releases and Financial updates are sent to those on the list.

If you wish to be removed from this list or your address has been accidentally included here, then please let us know by a return email and we will remove it. All the others will continue to be on the mailing list. If you wish to receive emails on some other email id, please send it to us. If you think that somebody else from your organisation should be added to this list, then please ask him / her to send us an email and we will add. If you are changing jobs, please send us your new email id. We would like to be in touch with you and keep you updated on happenings at Sun Pharma.

We would be happy to host one-on-one, group and telephone meetings for updates on the Company. If you wish to setup such a meeting, feel free to get in touch with us. In-person meetings can be at our office or elsewhere depending on mutual convenience. Our contact details:

Uday Baldota Tel : +91 22 6645 5645, Ext 605 Tel Direct : +91 22 66455605 Mobile : +91 98670 10529 E mail: uday.baldota@sunpharma.com Mira Desai Tel : +91 22 6645 5645, Ext 606 Tel Direct : +91 22 66455606 Mobile : +91 98219 23797 E mail : mira.desai@sunpharma.com www.sunpharma.com

Posted: December 2007


View comments

Hide
(web2)